THC, CBD, and CBN Activate a Key Drug Metabolism Receptor — Especially in Humans | Research

The takeaway

All three major cannabinoids strongly activate the human pregnane X receptor at low concentrations, potentially altering how the body processes many common medications.

Pharmacologists, drug interaction researchers, clinicians prescribing alongside cannabinoids

What the researchers found

THC, CBD, and CBN activated human PXR at 10 μM by 28-fold, 23-fold, and 17-fold respectively — significantly more than rat or mouse PXR. The minimum effective concentration for human PXR was 0.3 μM, 10-33 times lower than for rodent PXR, suggesting species-specific drug interaction risks.

Why it matters

PXR controls the expression of drug-metabolizing enzymes like CYP3A4, which processes about half of all prescription drugs. If cannabinoids activate this receptor at low concentrations, they could significantly alter how medications work in cannabis users.

The numbers in context

Human PXR activation at 10 μM: THC 28-fold, CBD 23-fold, CBN 17-fold. Rat PXR: THC 9-fold, CBD 6-fold, CBN 4-fold. Mouse PXR: THC 4-fold, CBD 3-fold, CBN 3-fold. Human MEC: 0.3 μM (10-33x lower than rodent).

How the study worked

Concentration-response analysis using dual-luciferase reporter gene assays in human, rat, and mouse PXR-transfected HepG2 cells. Mammalian one-hybrid and two-hybrid assays confirmed ligand-binding domain transactivation and coactivator recruitment.

What this study cannot tell us

In vitro cell line study — actual in vivo PXR activation depends on cannabinoid concentrations reaching the liver. Transfected cell system may not fully replicate physiological conditions. Clinical drug interaction magnitude not measured.

How to read the evidence

Rigorous in vitro pharmacology with multiple assay systems, but clinical relevance depends on achieving these concentrations in vivo.

When this study was published

Published 2026, addressing growing need for cannabinoid drug interaction data.

The bigger picture

The dramatic species difference — human PXR is activated at much lower cannabinoid concentrations than rodent PXR — means animal studies may significantly underestimate the drug interaction potential of cannabinoids in humans.

Questions still open

Do therapeutic cannabinoid doses achieve PXR-activating concentrations in the liver? Which specific drugs are most affected by cannabinoid-PXR-CYP3A4 interactions? Should cannabis users be screened for drug interactions?

Common questions

Can cannabis affect how other medications work?

This study found that THC, CBD, and CBN all strongly activate a receptor (PXR) that controls how the body breaks down about half of all prescription drugs — suggesting cannabis could potentially speed up or alter the processing of many medications.

Why are animal studies misleading for cannabis drug interactions?

Human PXR is activated by cannabinoids at concentrations 10-33 times lower than rat or mouse PXR, meaning animal experiments may seriously underestimate how much cannabis affects drug metabolism in people.

Read the original research

Species differences in pregnane X receptor activation by Δ-9-tetrahydrocannabinol, cannabidiol, and cannabinol.

Biochemical and biophysical research communications, 799, 153250

View on PubMed ↗Publisher’s paper ↗

Citation

Lau, Aik Jiang; Chang, Thomas K H. (2026). Species differences in pregnane X receptor activation by Δ-9-tetrahydrocannabinol, cannabidiol, and cannabinol.. Biochemical and biophysical research communications, 799, 153250. https://doi.org/10.1016/j.bbrc.2026.153250